Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma.

MLA

UCL - SSS/IREC/MONT - Pôle Mont Godinne, et al. “Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-Cell Lymphoma.” HemaSphere, Vol. 6, No. 2, p. E672 (2022), 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1328225988&authtype=sso&custid=ns315887.

APA

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d’hématologie, Houot, R., Poeschel, V., Altmann, B., Angel, S., Thurner, L., Illmer, T., André, M., Dreyling, M., Maisonneuve, H., Tilly, H., Mayer, S., Casasnovas, O., Le Gouill, S., Offner, F., Cartron, G., Kerkhoff, A., Weber, T., … Held, G. (2022). Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma. HemaSphere, Vol. 6, No. 2, p. E672 (2022).

Chicago

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d’hématologie, Roch Houot, Viola Poeschel, Bettina Altmann, Stephanie Angel, Lorenz Thurner, et al. 2022. “Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-Cell Lymphoma.” HemaSphere, Vol. 6, No. 2, p. E672 (2022). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1328225988&authtype=sso&custid=ns315887.